News & Updates
Filter by Specialty:

Fezolinetant reduces hot flashes during menopause
The neurokinin-3 receptor antagonist fezolinetant reduced the frequency and severity of menopause-associated vasomotor symptoms (VMS), according to results of the extension arm of the phase III Skylight 2 trial presented at ENDO 2022.
Fezolinetant reduces hot flashes during menopause
01 Aug 2022
Antenatal vitamin D supplementation may curb risk of infant eczema
Infants born to mothers who popped vitamin D during pregnancy are less likely to develop atopic eczema compared with their counterparts whose mothers received placebo, as shown in the UK Maternal Vitamin D Osteoporosis Study (MAVIDOS).
Antenatal vitamin D supplementation may curb risk of infant eczema
01 Aug 2022
Timing of liquid LT4 intake doesn’t impact bioavailability
Bioavailability studies presented at ENDO 2022 showed that patients with hypothyroidism can safely take the liquid formulations of levothyroxine (LT4) 15 or 30 minutes before meals, without having to worry about food effect on bioavailability.
Timing of liquid LT4 intake doesn’t impact bioavailability
01 Aug 2022
COVID-19 shots temporarily mess up menstrual cycle length
Women who receive COVID-19 jabs may experience short-term changes in their menstrual cycle length, particularly those who have short, long, or irregular cycles prior to vaccination, a study has found.
COVID-19 shots temporarily mess up menstrual cycle length
29 Jul 2022
Which drugs raise risk of urinary tract infections?
Some medications may directly cause the occurrence of urinary tract infections (UTIs), and a recent study presented at the 37th Annual European Association of Urology Congress (EAU 2022) has identified six drugs that appear to contribute to “significant reporting levels” for infections.